Randomized Trial of Pimecrolimus Cream plus Colchicine Tablets versus Colchicine Tablets in the Treatment of Genital Ulcers in Behcet's Disease

被引:19
作者
Koese, Osman [1 ]
Dinc, Ayhan [2 ]
Simsek, Ismail [2 ]
机构
[1] Gulhane Mil Med Acad, Dept Dermatol, TR-06018 Ankara, Turkey
[2] Gulhane Mil Med Acad, Dept Rheumatol, TR-06018 Ankara, Turkey
关键词
Pimecrolimus; Colchicine; Genital ulcers; Behcet's disease; TOPICAL CALCINEURIN INHIBITORS; MANAGEMENT; MANIFESTATIONS;
D O I
10.1159/000182257
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Recurrent and painful genital ulcers are the hallmark of Behcet's disease. Objective: To determine the efficacy of pimecrolimus (PIM) cream on the pain and healing time of genital ulcers. Methods: A total of 76 patients were randomized to either receive PIM cream plus colchicine (COL) tablets (1-2 g/day) or COL tablets (1-2 g/day) alone for 1 month. Clinical evaluations were performed in 68 patients at the baseline and on the 3rd, 7th, 10th, 14th and 28th days of treatment. Also, genital ulcer pain was evaluated using a verbal pain score at each visit. Safety was monitored through adverse event reporting and laboratory tests. Results: The mean healing time of genital ulcers was shorter in the PIM + COL group (4.2 +/- 1.5 days) than the COL group (4.7 +/- 1.8 days), without statistical significance (p = 0.399). Visual analog scale scores decreased in both groups significantly. Neither of the treatment modalities was found to be superior to the other; however, pain was relieved in 4.2 +/- 0.5 days in PIM + COL group and in 5.5 +/- 1.2 days in COL group in the intention to treat population (p = 0.023). Observed adverse events were transient. Conclusion: Compared to COL alone, COL + PIM cream shortens the pain duration without any significant effect on healing time. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:140 / 145
页数:6
相关论文
共 19 条
  • [11] The frequency of scarring after genital ulcers in Behcet's syndrome: a prospective study
    Mat, MC
    Goksugur, N
    Engin, B
    Yurdakul, S
    Yazici, H
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (05) : 554 - 556
  • [12] The multiple faces of Behcet's disease and its aetiological factors
    Önder, M
    Gürer, MA
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2001, 15 (02) : 126 - 136
  • [13] ONDER M, 2004, CLIN EXP RHEUMAT S34, V22, pS120
  • [14] SILMAN AJ, 1990, LANCET, V335, P1078
  • [15] Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice -: Analysis of a Swiss cohort
    Simon, Dagmar
    Luebbe, Jann
    Wuethrich, Brunello
    Wiesner, Alice
    Weber, M. Monika
    Laffitte, Emmanuel
    Anliker, Mark D.
    Schoeni, Martin H.
    Braathen, Lasse R.
    Schmid-Grendelmeier, Peter
    Bobalj, Nicole Gilgen
    Schneider, Dirk
    [J]. DERMATOLOGY, 2006, 213 (04) : 313 - 318
  • [16] Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus
    Stuetz, Anton
    Baumann, Karl
    Grassberger, Maximilian
    Wolff, Klaus
    Meingassner, Josef G.
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 141 (03) : 199 - 212
  • [17] Behcet's syndrome: disease manifestations, management, and advances in treatment
    Yazici, Hasan
    Fresko, Izzet
    Yurdakul, Sebahattin
    [J]. NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (03): : 148 - 155
  • [18] Yurdakul S, 2001, ARTHRITIS RHEUM-US, V44, P2686, DOI 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO
  • [19] 2-H